近日,由荣昌生物制药(烟台)有限公司自主研发的ADC新药RC48(disitamab vedotin,商品名:爱地希)已获得美国食品药品监督管理局(FDA)审批,获准在美国直接进行Ⅱ期临床试验,适应证为HER2阳性局部晚期或转移性尿路上皮癌。RC48是我国第一个进入临床研究的抗体偶联(ADC)药物。ADC药物是由单克隆抗体、连接子和毒素偶联而成,...
摘要:最近,FDA获准荣昌生物自主研发的ADC新药RC48(disitamab vedotin,爱地希)在美国直接进行Ⅱ期临床试验,适应证为HER2阳性局部 最近,FDA获准荣昌生物自主研发的ADC新药RC48(disIT(http://www.maoyihang.com/sell/l_25/)amab vedotin,爱地希)在美国直接进行Ⅱ期临床试验,适应证为HER2阳性局部晚期或转移性尿路上皮...
Disitamab vedotin (DV; RC48-ADC) is an investigational antibody鈥揹rug conjugate comprised of a novel HER2-directed monoclonal antibody, disitamab, conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable linker. DV elicits antitumor activity through multimodal mechanisms of action ...
E.D. Deeks Disitamab vedotin: first approval Drugs, 81 (16) (2021), pp. 1929-1935 CrossrefView in ScopusGoogle Scholar [17] Z. Fu, S. Li, S. Han, C. Shi, Y. Zhang Antibody drug conjugate: the "biological missile" for targeted cancer therapy Signal. Transduct. Target. Ther., ...